✨
AI Summary
- Richard Pazdur calls for diverse opinions in FDA advisory committee hearings.
- FDA questions sponsors on clinical trial diversity plan execution.
- Stealth BioTherapeutics' elamipretide application for Barth Syndrome is under review.